Solid Bioscience SEC Filings

Solid Biosciences Inc. (SLDB) reported an equity award to Chief Medical Officer Gabriel Brooks comprised of an employee stock option to purchase 142,500 shares at an exercise price of $6.17 and 71,250 restricted stock units (RSUs), both granted on 08/14/2025. The option expires on 08/14/2035 and both awards are held directly by the reporting person. The RSUs convert on a one-for-one basis to common stock. The awards vest over four years: 50% of the original shares vest on the second anniversary of the grant and 25% of the original shares vest each year thereafter until the fourth anniversary. The Form 4 was signed by an attorney-in-fact on 08/18/2025.

Jessie Hanrahan, identified as a Director and the company's Chief Regulatory Officer, acquired equity in Solid Biosciences Inc. (SLDB) on 08/14/2025. The filing reports an employee stock option to purchase 142,500 shares at a $6.17 exercise price and 71,250 restricted stock units (RSUs), each RSU representing a right to one share. Following the transactions Hanrahan beneficially owns 142,500 options and 71,250 RSUs. The awards were granted on the stated date and include vesting terms: 50% of the original RSU grant vests on the second anniversary of the grant date and 25% annually thereafter until the fourth anniversary. The form is signed by an attorney-in-fact on 08/18/2025.

Solid Biosciences (SLDB) reported an equity award to its President and CEO, Alexander Cumbo. On 08/14/2025 Mr. Cumbo was granted an employee stock option to buy 337,500 shares at an exercise price of $6.17 expiring 08/14/2035, and 168,750 restricted stock units (RSUs) each representing one share. Following the grants, he beneficially owns 337,500 option shares and 168,750 RSUs, all held directly. The RSUs and the option were granted the same date and vest over four years: 50% of the original number vests on the second anniversary and 25% of the original number vests on each of the third and fourth anniversaries. The Form 4 was signed on 08/18/2025 by an attorney-in-fact for Mr. Cumbo.

RA Capital and affiliated persons report owning 7,997,510 shares of Solid Biosciences (SLDB), representing approximately 9.9% of the outstanding common stock. The reported position includes 5,673,193 shares directly held by RA Capital Healthcare Fund, L.P., additional small direct holdings through related accounts and pre-funded warrants exercisable for up to 3,722,085 shares subject to a beneficial ownership blocker that prevents exercise above 9.99% ownership. Recent open-market purchases disclosed include 529,768 shares at a weighted-average of $4.49 and smaller buys at prices between $3.80 and $4.50 per share. RA Capital, Peter Kolchinsky and Rajeev Shah disclose shared voting and dispositive power over the reported shares and state delegations of voting/dispositive authority from certain funds.

Solid Biosciences Inc. Schedule 13G/A filing by Commodore Capital entities

Commodore Capital LP and Commodore Capital Master LP filed an amendment to Schedule 13G reporting zero shares beneficially owned of Solid Biosciences Inc. (CUSIP 83422E204), representing 0.0% of the class. The filing lists the issuers' principal office at 500 Rutherford Avenue, Charlestown, Massachusetts, and gives filing addresses for the two filers in New York and the Cayman Islands. Both filers state no sole or shared voting or dispositive power over any shares and certify the securities were not acquired to influence control of the issuer. The filing is signed by Michael Kramarz for both entities and references a Joint Filing Agreement as an exhibit.

Solid Biosciences Inc. (SLDB) reported expanded clinical progress and a strengthened balance sheet while continuing to record sizable operating losses. As of June 30, 2025 the company held $138.9 million in cash and cash equivalents and $129.2 million in available-for-sale securities, totaling $268.1 million of liquid resources (excluding $1.9 million restricted cash). Total assets were $308.3 million and total liabilities were $50.0 million, leaving stockholders' equity of $258.3 million.

The company posted net losses of $39.5 million and $78.8 million for the three and six months ended June 30, 2025, respectively, driven by research and development spending of $32.4 million and $63.3 million for the same periods. Clinical and regulatory milestones include SGT-003 dosing (15 participants dosed as of August 12, 2025) with reported initial biopsy expression of microdystrophin averaging 110%, SGT-212 IND clearance (Dec 2024), and SGT-501 IND clearance and Health Canada CTA approval (July 2025). The February 2025 offering generated approximately $188.0 million of net proceeds. The company expects its cash, cash equivalents and securities to fund operations into the first half of 2027.

Form 4 highlights: On 07/06/2025, Solid Biosciences Inc. (SLDB) director Ian F. Smith acquired 4,573 common shares through the mandatory conversion (Code M) of previously granted restricted stock units (RSUs). The RSUs, issued on 01/06/2025, vest in four equal quarterly tranches and convert to common stock on a 1-for-1 basis. Following the transaction, Smith now directly owns 122,119 common shares and retains 9,146 unvested RSUs. The RSUs will accelerate in full if the Executive Chair Agreement terminates early or upon a change in control of the company. No shares were sold, suggesting continued insider exposure to SLDB’s equity. The filing was signed on 07/08/2025.

Solid Biosciences (NASDAQ:SLDB) filed a routine Form 4 disclosing that director Georgia Keresty received a stock-option grant covering 77,500 shares on 06/12/2025 at an exercise price of $4.58 per share.

The option vests in full on the earlier of the one-year anniversary of the grant or immediately prior to the next annual shareholder meeting, and accelerates upon certain change-in-control events. It expires on 06/12/2035. No open-market purchases or sales of common stock were reported, and Keresty’s beneficial ownership now reflects only the newly granted option, held directly.